Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
about
The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjectsEscitalopram effects on insula and amygdala BOLD activation during emotional processing.Efficacy and safety of generic escitalopram versus Lexapro in the treatment of major depression: a multicenter double-blinded randomized controlled trialSubchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers.Escitalopram, a selective serotonin reuptake inhibitor, inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells.Psychotherapeutic benefits of opioid agonist therapy.Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transportersExtended release drug delivery strategies in psychiatry: theory to practiceDepression rating scales in Parkinson's disease: critique and recommendations.Comparative efficacy of escitalopram in the treatment of major depressive disorder.Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptorsThe use of tricyclic antidepressants and selective serotonin reuptake inhibitors in women who are breastfeeding.Escitalopram: better treatment for depression is through the looking glass.Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.In vivo investigation of escitalopram's allosteric site on the serotonin transporterThe use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders.Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study.The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.Portal infusion of escitalopram enhances hepatic glucose disposal in conscious dogs.Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.Escitalopram induced mania.Effect of escitalopram on the processing of emotional faces.Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.Anxiolytic and panicolytic effects of escitalopram in the elevated T-maze.The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects.The importance of serotonin and noradrenaline in anxiety.Escitalopram block of hERG potassium channels.Efficacy of escitalopram oxalate for patients with post-stroke depression.Cost-Effectiveness Analysis of Escitalopram Compared with Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom
P2860
Q24678878-C7CF3E60-06D7-443C-9538-CFEB28A86B5CQ33730062-B70BE096-969D-4F23-857F-59C3F8F23712Q33744405-47CA1C13-54D8-4CA6-B63B-83B302BC8387Q33758489-079AFA06-3B66-4B6C-8940-AE124A7FD899Q33899055-05C708D5-AF19-426D-B69F-7C103C7374C6Q34014407-0CA30BD2-8740-43F8-BD2E-B2ADBF4500BDQ34102188-17F40C02-7214-4E1D-8BA2-BF39DF702020Q34396625-DCB38819-8A41-47DF-B143-9743E04AF548Q34578187-9E226C89-0FB7-4577-99A3-57B32DB715B9Q34664591-43B89CFC-3241-4C23-8908-D911317F8F9FQ35047176-FDEDC113-C735-4A6C-88A8-B231219C7356Q36103341-2021CD21-CE13-4A8C-A3AF-B2EED1E48F17Q36106846-2BF6BD75-8AB5-4854-BFC9-F03CA52329FAQ36479510-07A3447D-21CA-49F6-AA6E-834334B389A0Q36494042-6907FB29-DF18-4FAC-B9CF-C54CFF152F21Q36960563-F992886E-6F3C-44C9-866A-EDF36D5A3731Q37195414-40D183AD-FC12-4715-8A80-321C603AC752Q37207545-1C28944E-B9BB-4C59-A57C-A09EA4065EEEQ37417085-23F77B11-FFDC-43C3-9477-88DFB1CCAF4EQ37661849-7D0D5010-996A-462A-B4B5-3BC1DF5A6D54Q38167693-AABE75D4-5556-455A-B387-1CB51BE72B19Q42568767-F3D3BD58-C489-4C08-852E-102A488F7A1EQ43140028-E758F961-DC25-4E1F-8E70-76B9FFAE51A2Q45251058-C46C53E1-32CB-45B3-B1C5-963F0966DECDQ46798751-3AC104AF-6DCC-4AA3-9CDA-FBFD41401672Q46807637-3B4C44C8-6F84-4F29-828C-21CE24EDEBD3Q48324468-514F2312-0842-4B56-B3EB-923E10269771Q48424438-9F8A1CA2-A06F-4037-9D65-B79EAA094750Q53417601-D4B57DEF-0143-4C7C-BA40-C69EA0B57BBFQ56909928-0D1E761F-4E2D-446B-8C7C-CE98874D3918
P2860
Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Escitalopram : a review of its ...... ressive and anxiety disorders.
@ast
Escitalopram : a review of its ...... ressive and anxiety disorders.
@en
Escitalopram : a review of its ...... ressive and anxiety disorders.
@nl
type
label
Escitalopram : a review of its ...... ressive and anxiety disorders.
@ast
Escitalopram : a review of its ...... ressive and anxiety disorders.
@en
Escitalopram : a review of its ...... ressive and anxiety disorders.
@nl
prefLabel
Escitalopram : a review of its ...... ressive and anxiety disorders.
@ast
Escitalopram : a review of its ...... ressive and anxiety disorders.
@en
Escitalopram : a review of its ...... ressive and anxiety disorders.
@nl
P1433
P1476
Escitalopram : a review of its ...... ressive and anxiety disorders.
@en
P2093
John Waugh
Karen L Goa
P304
P356
10.2165/00023210-200317050-00004
P577
2003-01-01T00:00:00Z
P5875
P6179
1037817249